Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

Eli Lilly is experiencing explosive growth thanks ... and the company's momentum in the GLP-1 realm seems to be the only thing Wall Street analysts are talking about these days.

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE ... in the GLP-1 realm seems to be the only thing Wall Street analysts are talking about these days.

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...

The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...

NEW YORK (AP) — Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other ... eased to 4.36% from 4.39%. On Wall Street, KB Home rose ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Truist Securities, TD Cowen, Citigroup Inc. ( C) and Canaccord Genuity all also rate BSX "buy," while JPMorgan Chase & Co. ( ...